Preclinical but seriously powerful...well, at least on mice, but wow...
we are talking about up to 120x stronger CD8⁺ T cell responses....
A new preclinical study reports a molecule called SABER that could greatly improve cancer and infectious disease vaccines. SABER fuses antigens to a STING agonist and delivers them straight to the endoplasmic reticulum of dendritic cells—a “last mile” step critical for strong CD8⁺ T cell activation.
In mice, SABER-based vaccines significantly outperformed conventional adjuvants, fueling far higher CD8⁺ T cell responses, controlling tumor growth (even curing colorectal cancer models).
Along with boosting antibody production in a subunit vaccine, SABER shows promise for broad protection. Human trials are the next step, positioning SABER as a potential game-changer for future vaccine design.
Invitro study shows Delta Tocotrienol overcomes Docetaxel resistence in PCa
Seminal Vesicle Invasion & Senescent tumor cells.
